Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Cambrex (NYSE: CBM ) , a life sciences company that provides active pharmaceutical ingredients (API) used in the manufacture of prescriptions and over-the-counter medication, tumbled as much as 15% after releasing first-quarter earnings results before the opening bell.
So what: For the quarter, Cambrex reported an 11% decline in revenue to $66.2 million, which the company attributed to the timing of certain branded and generic API orders. Gross margin for the quarter, subsequent to that order timing, dipped 8.2% to 25% as costs rose modestly. Net income tumbled 89% to $1.2 million, or $0.04 per share, compared to $11.4 million, or $0.37 per share in the year-ago quarter. By comparison, Wall Street had been expecting Cambrex to report a profit of $0.23 per share on $80.4 million in revenue. In other words, it missed the broad side of the barn! Cambrex did, however, reaffirm its full-year guidance of an 8%-12% increase in sales and $0.99-$1.10 in EPS.
Now what: Shares did get tagged for as much as a 15% loss earlier in the session, but they're now down less than 7% as of this writing, primarily because of Cambrex's EPS and sales reaffirmation. There's not a lot a company like Cambrex can do when its customers delay orders for a quarter or two. Generally, as long as a company's outlook remains consistent, days like today where short-term negative surprises stun investors can be bargain-hunting opportunities. With Cambrex capable of high single-digit or low double-digit growth for the foreseeable future, I'd certainly suggest that additional upside could be seen in shares over the long run.
Cambrex shares have soared over the past year, but even it could struggle to keep pace with this top stock over the long run
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.